Keeping Track: US FDA Clears Oncologics Tukysa And Jelmyto; Regeneron Anti-Ebola Cocktail Under Review

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track Feature image

The Food and Drug Administration approved two breakthrough-designated oncologics this week, including its fastest novel approval of 2020: Seattle Genetics Inc.’s Tukysa (tucatinib) for HER2-positive breast cancer.

New product submission news was light, headlined by Regeneron Pharmaceuticals Inc.’s Ebola virus therapy and a combined oral contraceptive...

More from US FDA Performance Tracker

More from Regulatory Trackers